Vaxcyte, Inc. (PCVX)


-0.57 (-2.37%)
Symbol PCVX
Price $23.43
Beta 0.448
Volume Avg. 0.42M
Market Cap 1.390B
Shares () -
52 Week Range 16.78-29.725
1y Target Est -
DCF Unlevered PCVX DCF ->
DCF Levered PCVX LDCF ->
ROE -43.37% Strong Sell
ROA -34.67% Strong Sell
Operating Margin -
Debt / Equity 12.31% Neutral
P/E -
P/B 3.89 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest PCVX news

Mr. Grant E. Pickering
NASDAQ Global Select

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.